Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs

REFERENCES

• Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: Therapeutic implications. J Hypertens. 1996;14: 1259–1263.
   PubMed Web of Science ®Google Scholar
• Mandhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet. 1995; 345:749–751.
   PubMed Web of Science ®Google Scholar
• Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Pennert K, Wedel H, Wikstrand J, Berglund G. Predictors of cardiovascular morbidity in treated hypertension: Results from the Primary Preventive Trial in Göteborg, Sweden. J Hypertens. 1985;3:167–176.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Robles NR. Calcium antagonists and renal failure progresión. Ren Fail. 2008;30:247–255.
   PubMed Web of Science ®Google Scholar
• Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo J, Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure. 2002;11:95–100.
   PubMed Web of Science ®Google Scholar
• Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, on behalf of the COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932–940.
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000;35: 775–779.
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab. 2004; 17:259–266.
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39 (Suppl. 1):S1–S246.
   Google Scholar
• The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens. 1990;8:S187–S191.
   Google Scholar
• Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King A, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–1974.
   PubMed Web of Science ®Google Scholar
• Reams GP, Bauer JH. Acute and chronic effects of calcium antagonists on the essential hypertensive kidney. In Epstein M, Loutzenhiser R ( eds.). Calcium antagonists and the kidney. Philadelphia: Hanley & Belfus; 1990:247–256.
   Google Scholar
• Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993;44:545–550.
   PubMed Web of Science ®Google Scholar
• Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int. 1996;50:684–692.
   PubMed Web of Science ®Google Scholar
• Lewis E, Huncksicker LG, Clarke WR, Berl T, Pons MA, Lewis JB, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, , for the REIN 2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomized controlled trial. Lancet. 2005;365:939–946.
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med. 1996;156: 1938–1947.
   PubMedGoogle Scholar
• Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant. 1995;10 (Suppl. 9):39–45.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes. Am J Med. 2008;121: S16–S22.
   Web of Science ®Google Scholar
• Carmines PK, Navar LG. Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol. 1989;256:F1015–F1020.
   PubMed Web of Science ®Google Scholar
• Loutzenhiser R, Epstein M. Renal hemodynamic effects of calcium antagonists. In Epstein M, Loutzenhiser R ( eds.). Calcium antagonists and the kidney. Philadelphia: Hanley & Belfus;1990:33–74.
   Google Scholar
• Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol. 1987;253:F1157–F1163.
   PubMed Web of Science ®Google Scholar
• Dworkin LD. Effects of calcium channel blockers on glomerular injury on experimental glomerular injury. J Am Soc Nephrol. 1990;1:S21–S27.
   PubMed Web of Science ®Google Scholar
• Kanno Y, Suzuki H, Okada H, Saruta T. Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol. 1994;23:480–484.
   PubMed Web of Science ®Google Scholar
• Nagahama T, Hayashi K, Fujiwara K, Ozawa Y, Saruta T. Characterization of the renal action of pranidipine in the rat. Arzneimittel-Forsch. 2000;50:248–253.
   PubMed Web of Science ®Google Scholar
• Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension. 1991; 17:288–295.
   PubMed Web of Science ®Google Scholar
• Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol. 1987;252:F1003–F1010.
   PubMed Web of Science ®Google Scholar
• Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical determinant of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4:2023–2031.
   PubMed Web of Science ®Google Scholar
• Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockers on pressures transmission and glomerular injury in rat remnant kidneys. J Clin Invest. 1995; 96:793–800.
   PubMed Web of Science ®Google Scholar
• Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999;55:1849–1860.
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: A multicenter randomized controlled trial. Ren Fail. 2003;25:681–689.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: The AMANDHA study. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1347–1355.
   PubMedGoogle Scholar
• Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483–490.
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab. 2004;17:259–266.
   PubMedGoogle Scholar
• Robles NR, Ocon J, Gomez Campderá F, Manjon M, Pastor L, Herrera J, Lercanidipine in chronic renal failure patients: The ZAFRA Study. Ren Fail. 2005;27:73–80.
   PubMed Web of Science ®Google Scholar
• Ishitmitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis. Hypertens Res 2007; 30: 621–626.
   PubMedGoogle Scholar
• Düssing R. Angiotensin II-receptor blocker dosages: How high should we go? Int J Clin Pract. 2006;60:179–183.
   PubMedGoogle Scholar
• Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate essential hypertension in a double blind controlled study. J Cardiovasc Pharmacol. 1997;29 (Suppl. 2):S54–S58.
   Google Scholar
• Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin. Exp. Res. 2000;12:375–379.
   Google Scholar
• Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonists (either nifedipine or amlodipine) versus high-dose calcium antagonists monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182–1187.
   PubMed Web of Science ®Google Scholar